- Initial analysis of ongoing AQUARiUS trial indicates abiraterone acetate plus prednisone (AAP) provides significant benefit in cognitive outcome and fatigue in patients with metastatic castration-resistant prostate cancer (mCRPC) vs enzalutamide.
- No significant difference was observed in pain outcome.
Why this matters
- Both treatments improved survival of mCRPC; differences in patient-reported outcomes (PROs) may help physicians choose the most appropriate treatment in specific patients.
- Final data are needed to confirm initial findings.
- AQUARiUS is an ongoing, 2-cohort, phase 4 European study.
- 105 patients were evaluated at 3 months: 46 patients were treated with AAP and 59 received enzalutamide.
- Funding: Janssen Pharmaceutica N.V.
- At 3 months, AAP vs enzalutamide significantly improved:
- Cognitive impairment (Functional Assessment of Cancer Therapy-Cognitive Function): mean difference (MD), 6.64; P=.025.
- Cognitive functioning (Quality of Life Questionnaire-C30 [QLQ-C30]): MD, 11.82; P=.035.
- Usual level of fatigue (Brief Fatigue Inventory-Short Form [BFI-SF]): MD, −1.41; P=.038.
- Fatigue interference (BFI-SF): MD, −1.20; P=.036.
- Current fatigue (BFI-SF): MD, −1.41; P=.017.
- Worse level of fatigue (BFI-SF): MD, −1.63; P=.019.
- Fatigue (QLQ-C30): MD, −16.20; P=.009.
- Pain (QLQ-C30): MD, −13.59; P=.017.
- No significant differences between cohorts were observed for pain (Brief Pain Inventory-Short Form) at any time-point.
- Observational study.